文献速递冠心病

急性冠脉综合征稳定后连续高敏肌钙蛋白T变化与后续心血管事件的相关性

Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.
PubMed 文献 · JAMA Cardiol · 2022-01-01

该研究为IMPROVE-IT试验的二次分析,纳入6035例ACS稳定后患者,检测第1个月和第4个月的高敏肌钙蛋白T(hsTnT)。结果显示,hsTnT绝对升高≥7 ng/L与复合终点风险增加3倍以上相关(aHR 3.33),而降低≥7 ng/L风险相似或更低,提示连续监测hsTnT可能优化风险分层。

要点

  • ACS稳定后患者连续监测hsTnT变化与后续心血管事件风险呈梯度相关。
  • hsTnT升高≥7 ng/L者复合终点风险显著增加(aHR 3.33)。
  • hsTnT降低≥7 ng/L者风险与稳定者相似或更低(aHR 0.51)。

核心结论

  • 在ACS稳定后患者中,hsTnT变化与后续心血管事件风险呈梯度相关,连续评估可能优化风险分层并指导治疗决策。

研究设计与样本

  • IMPROVE-IT随机临床试验的二次分析,纳入6035例同意生物标志物亚研究且第1个月和第4个月有hsTnT数据的ACS住院患者。

主要发现

  • 大多数患者(4114例,68.2%)hsTnT变化稳定(变化<3 ng/L),1158例(19.2%)变化3至<7 ng/L,763例(12.6%)变化≥7 ng/L。
  • 校正临床危险因素并按第1个月hsTnT水平分层后,hsTnT绝对升高≥7 ng/L与复合终点风险增加3倍以上相关(aHR 3.33;95% CI 1.99-5.57;P < .001)。
  • hsTnT降低≥7 ng/L与风险相似或更低相关(aHR 0.51;95% CI 0.26-1.03;P = .06)。
  • 从较大绝对降低(aHR 0.51)到较大绝对升高(aHR 3.33)与复合终点风险呈阶梯式关联(P趋势<.001)。

临床怎么用

  • 对ACS稳定后患者,可考虑连续监测hsTnT以细化风险分层,并可能据此指导治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Studies have demonstrated an association between single measures of high-sensitivity troponin (hsTn) and future cardiovascular events in patients with chronic coronary syndromes. However, limited data exist regarding the association between changes in serial values of hsTn and subsequent cardiovascular events in this patient population. OBJECTIVE: To evaluate the association between changes in high-sensitivity troponin T (hsTnT) and subsequent cardiovascular events in patients stabilized after acute coronary syndrome (ACS). DESIGN, SETTING, AND PARTICIPANTS: This is a secondary analysis from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), a randomized clinical trial of ezetimibe vs placebo on a background of simvastatin in 18 144 patients hospitalized for an ACS across 1147 sites in 39 countries. The current biomarker substudy includes the 6035 participants consenting to the biomarker substudy with available hsTnT at months 1 and 4. Data were collected from October 26, 2005, through July 8, 2010, with the database locked October 21, 2014. Data were analyzed from February 28, 2021, through August 14, 2022. MAIN OUTCOMES AND MEASURES: The outcomes of interest were cardiovascular death, myocardial infarction (MI), stroke, or hospitalization for heart failure (HHF). Associations of absolute and relative changes in hsTnT between month 1 and month 4 as a function of the starting month 1 hsTnT and the composite outcome were examined using landmark analyses. RESULTS: Of 6035 patients in this analysis (median [IQR] age, 64 [57-71]), 1486 (24.6%) were female; 361 (6.0%) were Asian; 121 were (2.0%) Black; 252 (4.2%) were Spanish descent; 4959 were (82.2%) White; and 342 (5.7%) reported another race (consolidated owing to small numbers), declined to respond, or were not asked to report race owing to regulatory prohibitions. Most patients (4114 [68.2%]) had stable hsTnT values (change <3 ng/L), with 1158 (19.2%) and 763 (12.6%) having changes of 3 to less than 7 ng/L and 7 ng/L or more, respectively. After adjustment for clinical risk factors and stratification by the starting month 1 hsTnT level, an absolute increase in hsTnT of 7 ng/L or more was associated with a more than 3-fold greater risk of the composite outcome (adjusted hazard ratio [aHR], 3.33; 95% CI, 1.99-5.57; P < .001), whereas decreases of 7 ng/L or more were associated with similar to lower risk (aHR, 0.51; 95% CI, 0.26-1.03; P = .06) compared with stable values. There was a stepwise association moving from larger absolute decreases (aHR, 0.51; 95% CI, 0.26-1.03) to larger absolute increases (aHR, 3.33; 95% CI, 1.99-5.57) in hsTnT with future risk of the composite outcome (P trend <.001). A similar association was observed when analyzed on the basis of relative percent and continuous change. CONCLUSIONS AND RELEVANCE: Among stable patients post-ACS, changes in hsTnT were associated with a gradient of risk of subsequent cardiovascular events across the range of starting hsTnT values. Serial assessment of hsTnT may refine risk stratification with the potential to guide therapy decisions in this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00202878.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Patel, Qamar, Giugliano, et al. Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT. JAMA Cardiol. 2022. PMID: 36260325. doi:10.1001/jamacardio.2022.3627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。